Unknown

Dataset Information

Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.


ABSTRACT: A Bayesian design is presented that does precision dose finding based on time to toxicity in a phase I clinical trial with two or more patient subgroups. The design, called Sub-TITE, makes sequentially adaptive subgroup-specific decisions while possibly combining subgroups that have similar estimated dose-toxicity curves. Decisions are based on posterior quantities computed under a logistic regression model for the probability of toxicity within a fixed follow-up period, as a function of dose and subgroup. Similarly to the time-to-event continual reassessment method (TITE-CRM, Cheung and Chappell), the Sub-TITE design downweights each patient's likelihood contribution using a function of follow-up time. Spike-and-slab priors are assumed for subgroup parameters, with latent subgroup combina

SUBMITTER: Chapple AG 

PROVIDER: S-EPMC6640643 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature